Co-mutations in key tumor suppressor genes (KEAP1, SMARCA4, and CDKN2A) define different subgroups of KRASG12C-mutant NSCLC with clearly different clinical outcomes with OFF-state KRASG12C inhibitors. This evidence concerns the gene CDKN2A and non-small cell lung carcinoma.